| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding | |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | Entrez:930 MIM:107265 HGNC:HGNC:1633 Ensembl:ENSG00000177455 AllianceGenome:HGNC:1633 | |
| Description | CD19 molecule | |||||
| GTO ID | GTC1119 |
| Trial ID | JPRN-jRCT2053200162 |
| Disease | Large B-Cell Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | Breyanzi|Lisocabtagene maraleucel|liso-cel|JCAR017 |
| Location approved | US, Japan, EU, Switzerland, UK, Canada |
| Phase | Phase3 |
| Recruitment status | Recruiting |
| Title | Expanded Access Protocol (EAP) for Subjects Receiving Lisocabtagene Maraleucel that is Nonconforming for Commercial Release |
| Year | 2021 |
| Country | Japan |
| Company sponsor | Bristol-Myers Squibb |
| Other ID(s) | NCT04400591 |
| Cohort 1 | |||||||||||
|
|||||||||||